Skip to content
Search

Latest Stories

Issa brothers' partner assures resilience amid debt concerns

Gary Lindsay, managing partner of TDR Capital, has said that Asda can navigate higher borrowing costs

Issa brothers' partner assures resilience amid debt concerns

SUPERMARKET chain Asda's private equity co-owner, TDR Capital, has downplayed worries over the supermarket's debt load, stating confidence in its ability to manage increased borrowing costs, reported The Telegraph.

Gary Lindsay, managing partner of TDR Capital, which co-owns Asda with billionaire brothers Mohsin and Zuber Issa, assured MPs of the Business Select Committee that Asda can navigate higher borrowing costs.


He dismissed concerns surrounding the substantial debt of £4.2 billion. The co-owners addressed MPs amid apprehensions regarding the impact of rising interest rates on Asda's financial stability.

The takeover of Asda by the Issas and TDR, valued at £6.8bn and finalised in early 2021, was marked by a substantial debt component.

Initially secured during a period of record-low interest rates at 0.1 per cent, borrowing costs have since surged to 5.25 per cent, posing challenges as Asda considers debt refinancing.

Despite the sharp increase in borrowing costs, Lindsay expressed confidence in Asda's ability to manage its current debt levels. He reassured the committee, stating, "We feel more than comfortable with the leverage level at Asda."

“We feel more than comfortable that when we decide to refinance the balance sheet in the next two or three years that the business can more than absorb that incremental cost," he was quoted as saying.

“We’ve invested organically £1.3bn in the business. That’s on some stores and clearly a very significant investment in colleagues.”

The debt-fueled takeover involved TDR and the Issa brothers expanding its reach by acquiring over 100 Co-op stores and the UK assets of the Issas' petrol station business, EG Group.

Lindsay emphasised that the debt concerns were part of the broader strategy to grow Asda.

Responding to concerns over fuel prices, TDR denied any intentional strategy to increase profits and emphasised the company's competitiveness in pricing across its business.

Emma Gilks, deputy general counsel at TDR, who joined Lindsay, defended the Asda setup as “extremely transparent”.

"The transparency of the Asda structure, considering its size and scale, is not uncommon. We consider it entirely fitting," she said.

Lindsay's appearance before the committee marks the third instance of Asda's backers addressing MPs. Previous sessions saw Mohsin Issa facing criticism for perceived evasiveness and later being recalled due to alleged misleading statements.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less